• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Transactions of the American Ophthalmological Society. >Long-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis)
【24h】

Long-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis)

机译：半剂量维替泊芬光动力疗法治疗中央性浆液性脉络膜视网膜病变的长期结果（美国眼科学会论文）

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose: To evaluate whether half-dose verteporfin photodynamic therapy (PDT) is better than natural history for the treatment of central serous chorioretinopathy (CSC). Methods: Retrospective review of consecutive CSC patients treated with half-dose verteporfin PDT or untreated with observation and a minimum follow-up of 36 months. The main outcome measures included mean change in visual acuity and CSC recurrence. Survival analysis was performed to compare the CSC recurrence rates between the two groups. Results: A total of 192 eyes of 192 patients were included; 75 eyes were treated with half-dose verteporfin PDT and 117 were untreated. The mean follow-up duration was 74.1 months. At the last follow-up, the mean logMAR visual acuity was significantly better in the half-dose verteporfin PDT group compared with the untreated control group ( P =.005). The mean visual improvement of the half-dose verteporfin PDT group at the last follow-up was 1.8 lines, compared with 0.0 line in the untreated control group ( P <.001). Recurrence of CSC developed in 15 eyes (20%) in the half-dose verteporfin PDT group compared with 63 eyes (53.8%) in the untreated control group ( P <.001). Survival analysis demonstrated that eyes treated with half-dose verteporfin PDT were significantly less likely to develop CSC recurrence compared with untreated controls ( P <.001). Regression analysis showed that half-dose verteporfin PDT was the only significant factor in reducing the risk of CSC recurrence. Conclusions: Half-dose verteporfin PDT for the treatment of CSC resulted in significantly better visual acuity outcomes and lower recurrence rate in the long term compared with untreated controls.
机译：目的：评估半剂量维替泊芬光动力疗法（PDT）是否优于自然史治疗中央性浆液性脉络膜视网膜病变（CSC）。方法：回顾性研究连续的CSC患者接受半剂量Verteporfin PDT治疗或未经观察治疗，至少随访36个月。主要结局指标包括视力和CSC复发的平均变化。进行生存分析以比较两组之间的CSC复发率。结果：共纳入192例患者的192只眼。用半剂量维替泊芬PDT治疗75眼，未治疗117眼。平均随访时间为74.1个月。在最后一次随访中，半剂量维替泊芬PDT组的平均logMAR视力明显好于未治疗的对照组（P = .005）。在最后一次随访中，半剂量维替泊芬PDT组的平均视觉改善为1.8线，而未经治疗的对照组为0.0线（P <.001）。半剂量维替泊芬PDT组中有15只眼（20％）发生了CSC的复发，而未治疗的对照组中有63只眼（53.8％）出现了CSC的复发（P <.001）。生存分析表明，与未治疗的对照组相比，用半剂量Verteporfin PDT治疗的眼睛发生CSC复发的可能性明显降低（P <.001）。回归分析表明，半剂量维替泊芬PDT是降低CSC复发风险的唯一重要因素。结论：与未治疗的对照组相比，长期使用半剂量维替泊芬PDT治疗CSC可显着改善长期视力，降低复发率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号